StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Nirav Chheda, Nirmal Bang Securities

BUYGlenmark Pharmaceuticals

byNirav Chheda, Nirmal Bang SecuritiesHorizon: NA (inferred Swing (≤2wk))24 Aug 2026via Zee Business (Live)

Entry₹2,365.5Inferred
Target₹2,450
Total upside +3.57% (call closed)
Stop loss₹2,330-1.50% risk
Exit₹2,45026 Aug 2026, 10:00 am
Target hit+3.57%0.00%upside left
Follow Nirav Chheda for new calls(21% target hit, 71 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 182 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 26 Aug 2026
4 supporting1 neutral1 opposing
Supports the BUY call (4)

5 advisors have active short-term BUY calls on this stock, with 4 issued in the last 14 days

Advisor consensus · adjacent horizon·26 Aug · today

Glenmark Pharmaceuticals Inc., USA has launched a new Calcium Gluconate Injection product in various strengths and vial sizes.

BSE · Company Update·21 Aug · 5d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·21 Aug · 5d ago

Glenmark Pharmaceuticals has received approval from the U.S. FDA for its Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray.

BSE · Company Update·20 Aug · 6d ago

(opens in new tab)
Neutral / worth noting (1)

Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s

BSE · Company Update·11 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

NewsCnbc-Tv18·12 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.